This research focuses on advanced methods for administering medicines more directly, for example in the colon (large intestine). An example is Infliximab, a drug that is administered directly to the biophase to treat conditions including Crohn’s disease and ulcerative colitis. This drug is currently administered systemically, and has a number of side effects. The hypothesis is that local administration is more effective and will have fewer side effects.
The first patient studies with this new drug form are due to begin soon. These will be conducted in cooperation with the Pharmaceutical Technology and Biopharmacy section of the Pharmacy department and the Department of Liver, Digestive and Metabolic Diseases at the UMCG.
There are plans to combine this type of research with pharmacokinetic research in the future. In the field of targeted treatments too, this can make an important contribution to treatment optimization in terms of both efficacy and safety.
Prof. dr. J.G.W. Kosterink
Head department Clinical Pharmacy and Pharmacology, hospital pharmacist